Cargando…
Apremilast in Refractory Alopecia Areata
Alopecia areata (AA) is a common disease characterized by nonscarring hair loss. There are no satisfactory therapies for extensive cases. Systemic immune suppressants are usually used despite their nonspecific actions and often associated side effects. Apremilast is an oral, small-molecule, inhibito...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830030/ https://www.ncbi.nlm.nih.gov/pubmed/31728104 http://dx.doi.org/10.4103/ijt.ijt_59_19 |
_version_ | 1783465696958611456 |
---|---|
author | Estébanez, Andrea Estébanez, Nuria Martín, Jose M Montesinos, Encarna |
author_facet | Estébanez, Andrea Estébanez, Nuria Martín, Jose M Montesinos, Encarna |
author_sort | Estébanez, Andrea |
collection | PubMed |
description | Alopecia areata (AA) is a common disease characterized by nonscarring hair loss. There are no satisfactory therapies for extensive cases. Systemic immune suppressants are usually used despite their nonspecific actions and often associated side effects. Apremilast is an oral, small-molecule, inhibitor of phosphodiesterase 4 approved for the treatment of psoriasis and psoriatic arthritis. Its use in AA has shown variable results. Whereas a recent reduced clinical trial concluded a lack of efficacity, several case reports demonstrate a significant improvement. We report four cases of extensive AA successfully treated with apremilast. |
format | Online Article Text |
id | pubmed-6830030 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-68300302019-11-14 Apremilast in Refractory Alopecia Areata Estébanez, Andrea Estébanez, Nuria Martín, Jose M Montesinos, Encarna Int J Trichology Case Report Alopecia areata (AA) is a common disease characterized by nonscarring hair loss. There are no satisfactory therapies for extensive cases. Systemic immune suppressants are usually used despite their nonspecific actions and often associated side effects. Apremilast is an oral, small-molecule, inhibitor of phosphodiesterase 4 approved for the treatment of psoriasis and psoriatic arthritis. Its use in AA has shown variable results. Whereas a recent reduced clinical trial concluded a lack of efficacity, several case reports demonstrate a significant improvement. We report four cases of extensive AA successfully treated with apremilast. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6830030/ /pubmed/31728104 http://dx.doi.org/10.4103/ijt.ijt_59_19 Text en Copyright: © 2019 International Journal of Trichology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Case Report Estébanez, Andrea Estébanez, Nuria Martín, Jose M Montesinos, Encarna Apremilast in Refractory Alopecia Areata |
title | Apremilast in Refractory Alopecia Areata |
title_full | Apremilast in Refractory Alopecia Areata |
title_fullStr | Apremilast in Refractory Alopecia Areata |
title_full_unstemmed | Apremilast in Refractory Alopecia Areata |
title_short | Apremilast in Refractory Alopecia Areata |
title_sort | apremilast in refractory alopecia areata |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830030/ https://www.ncbi.nlm.nih.gov/pubmed/31728104 http://dx.doi.org/10.4103/ijt.ijt_59_19 |
work_keys_str_mv | AT estebanezandrea apremilastinrefractoryalopeciaareata AT estebaneznuria apremilastinrefractoryalopeciaareata AT martinjosem apremilastinrefractoryalopeciaareata AT montesinosencarna apremilastinrefractoryalopeciaareata |